EQRX earnings

Revolution Medicines Expects to Conduct Late-Stage Development of RAS(ON) Inhibitor Drug Candidate Pipeline Supported by Fortified Balance Sheet Agreement is the Result of a Rigorous Process Conducted by Independent Transaction Committee of EQRx Board to Consider Strategic Alternatives to Maximize Value for EQRx Stockholders Transaction Expected to Close in November 2023 REDWOOD CITY, Calif. and CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. ("Revolution Medicines" or the "Company") (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, and EQRx, Inc. ("EQRx") (NASDAQ:EQRX) today announced a definitive agr

Company to utilize significant scale of capital and team to advance a pipeline of clinically differentiated, high-value therapiesPrioritizing development of lerociclib (CDK 4/6 inhibitor); initiated Phase 3 trial in first-line advanced endometrial cancer; enrollment in Phase 2 trial in first- and second-line advanced breast cancer near completion, providing a foundation for future combination development opportunitiesSeeking commercialization partnerships for aumolertinib (third-generation EGFR inhibitor)Terminating license agreements for sugemalimab (anti-PD-L1 antibody), nofazinlimab (anti-PD-1 antibody) and EQ121 (JAK-1 inhibitor)$1.3 billion in cash, cash equivalents and short-term inves

CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- EQRx, Inc. (NASDAQ:EQRX), a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of the most prevalent disease areas, including cancer and immune-inflammatory conditions, today announced it will host a conference call and webcast on Monday, May 8, 2023, at 4:30 p.m. ET to report its first quarter 2023 financial results and provide a business update. A live webcast of the call will be available on the "Investor Relations" page of the Company's website at https://investors.eqrx.com/news-events/events-presentations. To access the call by phone, participants should visit this link

For Investors Lerociclib: Ongoing Phase 2 trial in first- and second-line treatment of metastatic breast cancer; expect to initiate Phase 3 trial in advanced endometrial cancer in 1H 2023 Aumolertinib: MAAs accepted for review by MHRA and EMA for EGFR-mutated NSCLC Sugemalimab: MAAs accepted for review by MHRA and EMA for the first-line treatment of metastatic NSCLC in combination with chemotherapyEnded 2022 with $1.4 billion in cash, cash equivalents and short-term investments; anticipate runway into 20282023 cash used in operations is expected to be less than $275 million, enabled by efforts to increase operational efficiencies including a reduction in workforce CAMBRIDGE, Mass., Feb.

Application is based on data from the pivotal Phase 3 GEMSTONE-302 trial assessing sugemalimab in combination with chemotherapy as first-line treatment of metastatic non-small cell lung cancerAcceptance of the marketing authorization application (MAA) is EQRx's second from the United Kingdom's Medicines and Healthcare products Regulatory Agency after acceptance of aumolertinib MAA earlier this year CAMBRIDGE, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (NASDAQ:EQRX), a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of the most prevalent disease areas, including cancer and immune-inflammatory conditions, today anno

Submission is EQRx's first to European Medicines AgencyApplication is based on data from the pivotal Phase 3 AENEAS trial evaluating aumolertinib as first-line treatment of patients with EGFR-mutated non-small cell lung cancer CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (NASDAQ:EQRX), a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of the most prevalent disease areas, including cancer and immune-inflammatory conditions, today announced that the European Medicines Agency (EMA) has accepted for review its marketing authorization application (MAA) for aumolertinib, a third-generation epidermal growth factor

Aumolertinib: Clarity on path for potential U.S. approval; continue to pursue ex-U.S. approvals based on existing data, with MAA under review by U.K.'s MHRASugemalimab: Based on recent FDA feedback, EQRx has concluded that there is no commercially viable path for sugemalimab plus chemotherapy in Stage IV NSCLC in the U.S.; continue to pursue ex-U.S. approvals based on existing dataLate-stage pipeline: Prioritize development of aumolertinib and lerociclib, which could form the basis of future combination therapies for multiple cancer typesU.S. commercial strategy: Adopt market-based pricing for aumolertinib and lerociclib in the U.S. only  Strong financial position: $1.5 billion cash and shor

CAMBRIDGE, Mass., Oct. 28, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (NASDAQ:EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at substantially lower prices, today announced it will host a conference call and webcast on Thursday, November 10, 2022 at 8:00 a.m. ET to report its third quarter 2022 financial results and provide a business update. A live webcast of the call will be available on the "Investor Relations" page of the Company's website at https://investors.eqrx.com/news-events/events-presentations. To access the call by phone, participants should visit this link (registration link) to receive dial-in details. Participant

Initiated a U.S.-led, comparative Phase 3b clinical trial with aumolertinib for the first-line treatment of EGFR-mutated NSCLCAnnounced U.K. MHRA acceptance of EQRx's first regulatory submission (aumolertinib) for review; first sugemalimab regulatory submission expected ex-U.S. in 2H 2022; continue to engage in constructive conversations with the U.S. FDAPresented compelling new clinical data at recent medical meetings, including results from a study of aumolertinib in patients with NSCLC and CNS metastases (ASCO) and a late-breaking oral presentation of final PFS results of sugemalimab in Stage III NSCLC (WCLC)Expanded Global Buyers Club to over 210 million lives covered by payers and healt

In the ongoing GEMSTONE-301 Phase 3 study, sugemalimab, administered after treatment with either concurrent or sequential chemoradiotherapy, demonstrated a statistically significant improvement in progression-free survival versus placebo in patients with unresectable Stage III non-small cell lung cancer (NSCLC)There are currently no immunotherapy consolidation treatments in the U.S. or Europe approved for patients with unresectable Stage III NSCLC who have received sequential chemoradiotherapy CAMBRIDGE, Mass., Aug. 07, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (NASDAQ:EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radicall

CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (NASDAQ:EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today announced it will host a conference call and webcast on Thursday, August 11, 2022 at 8:00 a.m. ET to report its second quarter 2022 financial results and provide a business update. A live webcast of the call will be available on the "Investor Relations" page of the Company's website at https://investors.eqrx.com/news-events/events-presentations. To access the call by phone, participants should visit this link (registration link) to receive dial-in details. Participants are

Marketing authorization application is EQRx's first submission to a regulatory agencyApplication is based on data from pivotal Phase 3 AENEAS trial in the first-line treatment of EGFR-mutated non-small cell lung cancer CAMBRIDGE, Mass., June 14, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (NASDAQ:EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today announced that the United Kingdom (U.K.)'s Medicines and Healthcare products Regulatory Agency (MHRA) has accepted for review the marketing authorization application (MAA) for aumolertinib, a third-generation EGFR-tyrosine kinase inhibitor (TKI), in develop

New data on lead oncology programs aumolertinib and sugemalimab to be presented at the 2022 ASCO Annual Meeting, including pre-specified interim overall survival (OS) data from the Phase 3 GEMSTONE-302 study of sugemalimab plus chemotherapy in first-line Stage IV NSCLCContinue to expect first regulatory submissions for aumolertinib and sugemalimab ex-U.S. in 2H 2022; constructive conversations with the FDA are ongoing to gain greater clarity on the regulatory path forward in the U.S.Continue to advance the Global Buyers Club; first conversion of a memorandum of understanding (MOU) to a pre-commercialization agreementEQRx to host conference call and webcast today at 8:00 a.m. ET CAMBRIDGE, M

CAMBRIDGE, Mass., April 29, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (NASDAQ:EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today announced it will host a conference call and webcast on Friday, May 13, 2022 at 8:00 a.m. ET to report its first quarter 2022 financial results and provide a business update. A live webcast can be accessed by visiting the Investors section of the Company's website at investors.eqrx.com. The conference call can be accessed by dialing 855-718-8094 (domestic) or 484-747-6788 (international) and referring to conference ID 6893121. The webcast will be made available for replay

First presentation of data from a pre-specified interim overall survival analysis of the Phase 3 GEMSTONE-302 study of sugemalimab in patients with previously untreated Stage IV non-small cell lung cancer (NSCLC)Oral presentation featuring the primary analysis from Phase 2 GEMSTONE-201 study of sugemalimab in patients with relapsed or refractory extranodal NK/T-cell lymphoma (ENKTL), a rare and aggressive form of Non-Hodgkin lymphomaInitial presentation on the activity of aumolertinib in patients with central nervous system (CNS) metastases from Phase 3 AENEAS study in advanced EGFR-mutated NSCLC CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (NASDAQ:EQRX), a new type of

First regulatory submissions for lead oncology programs aumolertinib and sugemalimab are expected to be ex-U.S. in 2H 2022; continuing to engage in discussions with the FDAContinue expanding the Global Buyers Club; goal is to have MOUs in place with payers and health systems that cover approximately 350 million lives by the end of 2022Strong cash position with expected runway into 2025; $1.7 billion in cash and cash equivalents as of December 31, 2021EQRx to host conference call and webcast today at 8:00 a.m. ET CAMBRIDGE, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (NASDAQ:EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to

CAMBRIDGE, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (NASDAQ:EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today announced it will host a conference call and webcast on Wednesday, March 23, 2022, at 8:00 a.m. ET to report its fourth quarter and full year 2021 financial results and provide a business update. A live webcast can be accessed by visiting the Investors section of the Company's website at investors.eqrx.com. The conference call can be accessed by dialing 855-718-8094 (domestic) or 484-747-6788 (international) and referring to conference ID 4596972. The webcast will be made